MESO

REVASCOR® (Rexlemestrocel)

Advanced Heart Failure

Stage (next event)

Expected Date

Phase 3

Q4 2020

Catalyst Info & Data Links

TITLE: REVASCOR® (Rexlemestrocel) in Advanced Heart Failure - Phase 3 Data

  • ClinicalTrial.gov (NCT02032004): Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure. (DREAM HF-1)


WHAT IS THE CATALYST EVENT?

  • Phase 3 Data


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?


PRIOR DATA/EVENTS

PRESS RELEASES

posters and publications

Mechanism

MARKET

  • CHF prevalence is expected to grow 46% by 2030, affecting more than 8 million Americans (Learn more HERE). 

Updated by HC

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

ASCO 2018 Amp Noteworthy Abstracts

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon